Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00244855 · OUTCOME

Survival

Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma · Source last updated 2017-05-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Kaplan-Meier estimated % of patients
Interval / dispersion
95% Confidence Interval
Time frame
At 6 months, 12 months and 24 months after enrollment

What was measured

Percentage of patients remaining alive estimated according to the Kaplan-Meier method

Groups in this outcome

No Previous Treatment

Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies

Previous Treatment

Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
No Previous Treatment7
Previous Treatment25

Reported measurements

At 6 months
Values in Kaplan-Meier estimated % of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
No Previous Treatment96Not reported88100Not reported
Previous Treatment100Not reported100100Not reported
At 12 months
Values in Kaplan-Meier estimated % of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
No Previous Treatment96Not reported88100Not reported
Previous Treatment100Not reported100100Not reported
At 24 months
Values in Kaplan-Meier estimated % of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
No Previous Treatment91Not reported80100Not reported
Previous Treatment67Not reported38100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        88
        upper Limit
        100
        value
        96
      2. group Id
        OG001
        lower Limit
        100
        upper Limit
        100
        value
        100
    title
    At 6 months
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        88
        upper Limit
        100
        value
        96
      2. group Id
        OG001
        lower Limit
        100
        upper Limit
        100
        value
        100
    title
    At 12 months
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        80
        upper Limit
        100
        value
        91
      2. group Id
        OG001
        lower Limit
        38
        upper Limit
        100
        value
        67
    title
    At 24 months
denoms
  1. counts
    1. group Id
      OG000
      value
      7
    2. group Id
      OG001
      value
      25
    units
    Participants
description
Percentage of patients remaining alive estimated according to the Kaplan-Meier method
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    No Previous Treatment
  2. description
    Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
    id
    OG001
    title
    Previous Treatment
param Type
NUMBER
reporting Status
POSTED
time Frame
At 6 months, 12 months and 24 months after enrollment
title
Survival
type
SECONDARY
unit Of Measure
Kaplan-Meier estimated % of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice